Blood pressure level and kidney disease progression: Do we really need to go to 130/80 mm Hg?

被引：1
作者：
Abu Jawdeh, Bassam G. [1 ]
Rahman, Mahboob [1 ]
机构：
[1] Univ Hosp Case Med Ctr, Div Nephrol & Hypertens, Cleveland, OH 44106 USA
来源：
CURRENT HYPERTENSION REPORTS | 2009年 / 11卷 / 05期
关键词：
ANGIOTENSIN-CONVERTING-ENZYME; STAGE RENAL-DISEASE; DEPENDENT DIABETES-MELLITUS; 9 GENE MYH9; CARDIOVASCULAR OUTCOMES; HYPERTENSIVE PATIENTS; CLINICAL PROTEINURIA; RISK-FACTOR; FOLLOW-UP; INHIBITION;
D O I：
10.1007/s11906-009-0060-3
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
Current guidelines recommend a blood pressure goal of less than 130/80 mm Hg in patients with chronic kidney disease. Considerable epidemiologic observational data, post hoc analyses of clinical trials, and meta-analyses support this goal, particularly in patients with proteinuria. Although prospective clinical trials have not shown a clear benefit, recent data indicate that a longer duration of follow-up may be needed to assess the effects of different blood pressure goals. While we await the results of several ongoing and planned studies in this area, the current recommendations of a blood pressure goal less than 130/80 mm Hg appear reasonable.
引用
收藏
页码：363 / 367
页数：5
相关论文
共 73 条
  • [1] Anavekar NS, 2004, NEW ENGL J MED, V351, P1285, DOI 10.1056/NEJMoa041365
  • [2] Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans
    Appel, Lawrence J.
    Wright, Jackson T., Jr.
    Greene, Tom
    Kusek, John W.
    Lewis, Julia B.
    Wang, Xuelei
    Lipkowitz, Michael S.
    Norris, Keith C.
    Bakris, George L.
    Rahman, Mahboob
    Contreras, Gabriel
    Rostand, Stephen G.
    Kopple, Joel D.
    Gabbai, Francis B.
    Schulman, Gerald I.
    Gassman, Jennifer J.
    Charleston, Jeanne
    Agodoa, Lawrence Y.
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2008, 168 (08) : 832 - 839
  • [3] Enalapril versus metoprolol in primary hypertension - effects on the glomerular filtration rate
    Aurell, M
    Bengtsson, C
    Bjorck, S
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 1997, 12 (11) : 2289 - 2294
  • [4] Effects of an ACE inhibitor calcium antagonist combination on proteinuria in diabetic nephropathy
    Bakris, GL
    Weir, MR
    DeQuattro, V
    McMahon, FG
    [J]. KIDNEY INTERNATIONAL, 1998, 54 (04) : 1283 - 1289
  • [5] Effects of blood pressure level on progression of diabetic nephropathy - Results from the RENAAL study
    Bakris, GL
    Weir, MR
    Shanifar, S
    Zhang, ZX
    Douglas, J
    van Dijk, DJ
    Brenner, BM
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (13) : 1555 - 1565
  • [6] BANNISTER KM, 1995, CONTRIB NEPHROL, V111, P184
  • [7] Impact of achieved blood pressure on cardiovascular outcomes in the irbesartan diabetic nephropathy trial
    Berl, T
    Hunsicker, LG
    Lewis, JB
    Pfeffer, MA
    Porush, JG
    Rouleau, JL
    Drury, PL
    Esmatjes, E
    Hricik, D
    Pohl, M
    Raz, I
    Vanhille, P
    Wiegmann, TB
    Wolfe, BM
    Locatelli, F
    Goldhaber, SZ
    Lewis, EJ
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (07): : 2170 - 2179
  • [8] LONG-TERM EFFECTS OF ENALAPRIL AND NICARDIPINE ON URINARY ALBUMIN EXCRETION IN PATIENTS WITH CHRONIC RENAL-INSUFFICIENCY - A 1-YEAR FOLLOW-UP
    BIANCHI, S
    BIGAZZI, R
    BALDARI, G
    CAMPESE, VM
    [J]. AMERICAN JOURNAL OF NEPHROLOGY, 1991, 11 (02) : 131 - 137
  • [9] RENAL PROTECTIVE EFFECT OF ENALAPRIL IN DIABETIC NEPHROPATHY
    BJORCK, S
    MULEC, H
    JOHNSEN, SA
    NORDEN, G
    AURELL, M
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1992, 304 (6823): : 339 - 343
  • [10] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
    Brenner, BM
    Cooper, ME
    de Zeeuw, D
    Keane, WF
    Mitch, WE
    Parving, HH
    Remuzzi, G
    Snapinn, SM
    Zhang, ZX
    Shahinfar, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) : 861 - 869
12345678